ATE286720T1 - Pharmazeutische formulierungen auf basis fester dispersionen - Google Patents

Pharmazeutische formulierungen auf basis fester dispersionen

Info

Publication number
ATE286720T1
ATE286720T1 AT00977140T AT00977140T ATE286720T1 AT E286720 T1 ATE286720 T1 AT E286720T1 AT 00977140 T AT00977140 T AT 00977140T AT 00977140 T AT00977140 T AT 00977140T AT E286720 T1 ATE286720 T1 AT E286720T1
Authority
AT
Austria
Prior art keywords
solid dispersion
pharmaceutical formulations
solid dispersions
formulations based
disclosed
Prior art date
Application number
AT00977140T
Other languages
English (en)
Inventor
James J Fort
Steven L Krill
Devalina Law
Yihong Qiu
William R Porter
Eric A Schmitt
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23745019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE286720(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE286720T1 publication Critical patent/ATE286720T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00977140T 1999-11-12 2000-11-10 Pharmazeutische formulierungen auf basis fester dispersionen ATE286720T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43951499A 1999-11-12 1999-11-12
PCT/US2000/030910 WO2001034118A2 (en) 1999-11-12 2000-11-10 Solid dispersion pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ATE286720T1 true ATE286720T1 (de) 2005-01-15

Family

ID=23745019

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00977140T ATE286720T1 (de) 1999-11-12 2000-11-10 Pharmazeutische formulierungen auf basis fester dispersionen

Country Status (10)

Country Link
EP (1) EP1227797B1 (de)
JP (1) JP4815085B2 (de)
AT (1) ATE286720T1 (de)
CA (1) CA2390092C (de)
DE (1) DE60017444T2 (de)
DK (1) DK1227797T3 (de)
ES (1) ES2235991T3 (de)
MX (1) MXPA02004739A (de)
PT (1) PT1227797E (de)
WO (1) WO2001034118A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (de) 1999-11-12 2006-06-14 Abbott Laboratories Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CN1255185C (zh) * 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
JP2007517016A (ja) 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
BRPI0720472A2 (pt) 2006-12-22 2014-01-14 Yuhan Corp Dispersão sólida contendo revaprazan e processo para a preparação da mesma
JP5593013B2 (ja) * 2007-04-20 2014-09-17 株式会社感光社 固体型殺菌剤及び人体施用組成物
US20120121722A1 (en) 2008-12-18 2012-05-17 Anup Avijit Choudhury Atazanavir formulations
CA2837266A1 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
EP3569225A1 (de) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Feste dispersion mit ritonavir

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

Also Published As

Publication number Publication date
JP2003530310A (ja) 2003-10-14
CA2390092C (en) 2009-07-14
DE60017444T2 (de) 2006-02-09
JP4815085B2 (ja) 2011-11-16
WO2001034118A2 (en) 2001-05-17
WO2001034118A3 (en) 2002-01-10
PT1227797E (pt) 2005-05-31
MXPA02004739A (es) 2003-01-28
DE60017444D1 (de) 2005-02-17
EP1227797A2 (de) 2002-08-07
DK1227797T3 (da) 2005-05-30
ES2235991T3 (es) 2005-07-16
EP1227797B1 (de) 2005-01-12
CA2390092A1 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
ATE329579T1 (de) Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE60017444D1 (de) Pharmazeutische formulierungen auf basis fester dispersionen
ATE333265T1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
WO2003080023A3 (en) Fast dissolving dosage forms having reduced friability
WO2003000237A8 (en) Biodegradable polymer coompositions
MX358033B (es) Forma de dosificación farmacéutica sólida que comprende al menos un inhibidor de proteasa de hiv.
CA2322315A1 (en) Fast disintegrating tablets
AR020610A1 (es) Utilizacion de un copolimero de acido metacrilico de tipo c segun la farmacopea us national formulary usp/nf, como agente de desagregacion y el procedimiento de fabricaion de un comprimido con dicho copolimero
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2005065646A3 (en) Novel drug compositions and dosage forms
WO2004100857A3 (en) Highly plastic granules for making fast melting tablets
BG103425A (en) Pharmaceutical composition
MY127908A (en) Improved pharmaceutical formulations.
WO2000040205A3 (en) Sustained release formulation with reduced moisture sensitivity
SE0004671D0 (sv) Pharmaceutical formulation
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
ATE248588T1 (de) Geschmacksmaskierte zubereitungen
WO2001089317A3 (en) Dietary aids and methods of use thereof
PT1263413E (pt) Metodo de preparacao de dispersoes solidas
DE60041691D1 (de) Ph-unabhängige pharmazeutische formulierungen mit verlängerter freisetzung
SE0001916D0 (sv) Novel formulation
BR0011864A (pt) Formulações farmacêuticas
SE0003125D0 (sv) Modified polymers
WO2004096155A3 (en) Tablets and methods for modified release of hydrophilic and other active agents
ATE300293T1 (de) Pharmazeutische zusammensetzungen, die schwerlösliche arzneistoffe enthalten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1227797

Country of ref document: EP